Glycosphingolipids are modulators of disease pathogenesis in amyotrophic lateral sclerosis

Proceedings of the National Academy of Sciences of the United States of America

Volumn 112, Issue 26, 2015, Pages 8100-8105

  Dodge, James C ^a   Treleaven, Christopher M ^a   Pacheco, Joshua ^a   Cooper, Samantha ^a   Bao, Channa ^a   Abraham, Marissa ^a   Cromwell, Mandy ^a   Sardi, S Pablo ^a   Chuang, Wei Lien ^a   Sidman, Richard L ^b,c   Cheng, Seng H ^a   Shihabuddin, Lamya S ^a  

^a SANOFI   (France)

^b HARVARD MEDICAL SCHOOL   (United States)

^c SCHEPENS EYE RESEARCH INSTITUTE   (United States)

Author keywords

FALS; Motor neuron disease; Mouse models neurological disease; SALS

Indexed keywords

ALPHA GALACTOSIDASE; BETA GALACTOSIDASE; BETA N ACETYLHEXOSAMINIDASE; CERAMIDE; GALACTOSYLCERAMIDASE; GALACTOSYLCERAMIDE; GANGLIOSIDE GM1; GANGLIOSIDE GM3; GLOBOTRIAOSYLCERAMIDE; GLUCOCEREBROSIDASE 1; GLUCOCEREBROSIDASE 2; GLUCOSYLCERAMIDASE; GLUCOSYLCERAMIDE; GLYCOSPHINGOLIPID; LACTOSYLCERAMIDE; SUPEROXIDE DISMUTASE; UNCLASSIFIED DRUG; CERAMIDE GLUCOSYLTRANSFERASE; GLUCOSYLTRANSFERASE;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; ENZYME ACTIVITY; HUMAN; HUMAN TISSUE; HYDROLYSIS; MALE; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; SPHINGOLIPID METABOLISM; SPINAL CORD; SYNTHESIS; ANIMAL; ANTAGONISTS AND INHIBITORS; DISEASE MODEL; ENZYMOLOGY; GENETICS; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; TRANSGENIC MOUSE;

MUS;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; G(M3) GANGLIOSIDE; GLUCOSYLTRANSFERASES; GLYCOSPHINGOLIPIDS; HUMANS; INJECTIONS, INTRAVENTRICULAR; MALE; MICE; MICE, TRANSGENIC; SPINAL CORD; SUPEROXIDE DISMUTASE;

EID: 84937954662     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1508767112     Document Type: Article

References (50)

1. Renton AE, Chiò A, Traynor BJ (2014) State of play in amyotrophic lateral sclerosis genetics. Nat Neurosci 17(1):17-23.
2. Yu RK, Bieberich E, Xia T, Zeng G (2004) Regulation of ganglioside biosynthesis in the nervous system. J Lipid Res 45(5):783-793.
3. Nordström V, et al. (2013) Neuronal expression of glucosylceramide synthase in central nervous system regulates body weight and energy homeostasis. PLoS Biol 11(3):e1001506.
4. Zhao H, et al. (2007) Inhibiting glycosphingolipid synthesis improves glycemic control and insulin sensitivity in animal models of type 2 diabetes. Diabetes 56(5):1210-1218.
5. Inokuchi J (2009) Neurotrophic and neuroprotective actions of an enhancer of ganglioside biosynthesis. Int Rev Neurobiol 85:319-336.
6. Yim SH, Farrer RG, Hammer JA, Yavin E, Quarles RH (1994) Differentiation of oligodendrocytes cultured from developing rat brain is enhanced by exogenous GM3 ganglioside. J Neurosci Res 38(3):268-281.
7. Prokazova NV, Samovilova NN, Gracheva EV, Golovanova NK (2009) Ganglioside GM3 and its biological functions. Biochem Biokhim 74(3):235-249.
8. Chatterjee S, Pandey A (2008) The Yin and Yang of lactosylceramide metabolism: Implications in cell function. Biochim Biophys Acta 1780(3):370-382.
9. Ishibashi Y, Kohyama-Koganeya A, Hirabayashi Y (2013) New insights on glucosylated lipids: Metabolism and functions. Biochim Biophys Acta 1831(9):1475-1485.
10. Dawson G, Stefansson K (1984) Gangliosides of human spinal cord: Aberrant composition of cords from patients with amyotrophic lateral sclerosis. J Neurosci Res 12(2-3):213-220.
11. Salazar-Grueso EF, Routbort MJ, Martin J, Dawson G, Roos RP (1990) Polyclonal IgM anti-GM1 ganglioside antibody in patients with motor neuron disease and variants. Ann Neurol 27(5):558-563.
12. Stevens A, Weller M, Wiethölter H (1993) A characteristic ganglioside antibody pattern in the CSF of patients with amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 56(4):361-364.
13. Rapport MM, Donnenfeld H, Brunner W, Hungund B, Bartfeld H (1985) Ganglioside patterns in amyotrophic lateral sclerosis brain regions. Ann Neurol 18(1):60-67.
14. Dawkins JL, Hulme DJ, Brahmbhatt SB, Auer-Grumbach M, Nicholson GA (2001) Mutations in SPTLC1, encoding serine palmitoyltransferase, long chain base subunit-1, cause hereditary sensory neuropathy type I. Nat Genet 27(3):309-312.
15. Zhou J, et al. (2012) Spinal muscular atrophy associated with progressive myoclonic epilepsy is caused by mutations in ASAH1. Am J Hum Genet 91(1):5-14.
16. Boukhris A, et al. (2013) Alteration of ganglioside biosynthesis responsible for complex hereditary spastic paraplegia. Am J Hum Genet 93(1):118-123.
17. Martin E, et al. (2013) Loss of function of glucocerebrosidase GBA2 is responsible for motor neuron defects in hereditary spastic paraplegia. Am J Hum Genet 92(2):238-244.
18. Mitsumoto H, et al. (1985) Motor neuron disease and adult hexosaminidase A deficiency in two families: Evidence for multisystem degeneration. Ann Neurol 17(4):378-385.
19. Jellinger K, Anzil AP, Seemann D, Bernheimer H (1982) Adult GM2 gangliosidosis masquerading as slowly progressive muscular atrophy: Motor neuron disease phenotype. Clin Neuropathol 1(1):31-44.
20. Argov Z, Navon R (1984) Clinical and genetic variations in the syndrome of adult GM2 gangliosidosis resulting from hexosaminidase A deficiency. Ann Neurol 16(1):14-20.
21. Olsen MK, et al. (2001) Disease mechanisms revealed by transcription profiling in SOD1-G93A transgenic mouse spinal cord. Ann Neurol 50(6):730-740.
22. Lobsiger CS, Boillée S, Cleveland DW (2007) Toxicity from different SOD1 mutants dysregulates the complement system and the neuronal regenerative response in ALS motor neurons. Proc Natl Acad Sci USA 104(18):7319-7326.
23. Fidler JA, et al. (2011) Disease progression in a mouse model of amyotrophic lateral sclerosis: The influence of chronic stress and corticosterone. FASEB J 25(12):4369-4377.
24. Vorwerk CK (2001) Ganglioside patterns in human spinal cord. Spinal Cord 39(12):628-632.
25. Hannun YA, Obeid LM (2011) Many ceramides. J Biol Chem 286(32):27855-27862.
26. Cabrera-Salazar MA, et al. (2012) Systemic delivery of a glucosylceramide synthase inhibitor reduces CNS substrates and increases lifespan in a mouse model of type 2 Gaucher disease. PLoS ONE 7(8):e43310.
27. McEachern KA, et al. (2007) A specific and potent inhibitor of glucosylceramide synthase for substrate inhibition therapy of Gaucher disease. Mol Genet Metab 91(3):259-267.
28. Krebs S, Medugorac I, Röther S, Strässer K, Förster M (2007) A missense mutation in the 3-ketodihydrosphingosine reductase FVT1 as candidate causal mutation for bovine spinal muscular atrophy. Proc Natl Acad Sci USA 104(16):6746-6751.
29. Cutler RG, Pedersen WA, Camandola S, Rothstein JD, Mattson MP (2002) Evidence that accumulation of ceramides and cholesterol esters mediates oxidative stress-induced death of motor neurons in amyotrophic lateral sclerosis. Ann Neurol 52(4):448-457.
30. Gillard BK, Clement RG, Marcus DM (1998) Variations among cell lines in the synthesis of sphingolipids in de novo and recycling pathways. Glycobiology 8(9):885-890.
31. Kirby J, et al. (2011) Phosphatase and tensin homologue/protein kinase B pathway linked to motor neuron survival in human superoxide dismutase 1-related amyotrophic lateral sclerosis. Brain 134(Pt 2):506-517.
32. Won JS, Singh AK, Singh I (2007) Lactosylceramide: A lipid second messenger in neuroinflammatory disease. J Neurochem 103(Suppl 1):180-191.
33. Frakes AE, et al. (2014) Microglia induce motor neuron death via the classical NF-κB pathway in amyotrophic lateral sclerosis. Neuron 81(5):1009-1023.
34. Mitsias P, Levine SR (1996) Cerebrovascular complications of Fabry's disease. Ann Neurol 40(1):8-17.
35. Zhong Z, et al. (2008) ALS-causing SOD1 mutants generate vascular changes prior to motor neuron degeneration. Nat Neurosci 11(4):420-422.
36. Suzuki K (2003) Globoid cell leukodystrophy (Krabbe's disease): Update. J Child Neurol 18(9):595-603.
37. Kang SH, et al. (2013) Degeneration and impaired regeneration of gray matter oligodendrocytes in amyotrophic lateral sclerosis. Nat Neurosci 16(5):571-579.
38. Wang XQ, Sun P, Paller AS (2003) Ganglioside GM3 inhibits matrix metalloproteinase-9 activation and disrupts its association with integrin. J Biol Chem 278(28):25591-25599.
39. Kaplan A, et al. (2014) Neuronal matrix metalloproteinase-9 is a determinant of selective neurodegeneration. Neuron 81(2):333-348.
40. Haidet-Phillips AM, et al. (2011) Astrocytes from familial and sporadic ALS patients are toxic to motor neurons. Nat Biotechnol 29(9):824-828.
41. Re DB, et al. (2014) Necroptosis drives motor neuron death in models of both sporadic and familial ALS. Neuron 81(5):1001-1008.
42. Kiskinis E, et al. (2014) Pathways disrupted in human ALS motor neurons identified through genetic correction of mutant SOD1. Cell Stem Cell 14(6):781-795.
43. Sheikh KA, et al. (1999) Mice lacking complex gangliosides develop Wallerian degeneration and myelination defects. Proc Natl Acad Sci USA 96(13):7532-7537.
44. Ohmi Y, et al. (2011) Gangliosides are essential in the protection of inflammation and neurodegeneration via maintenance of lipid rafts: Elucidation by a series of ganglioside-deficient mutant mice. J Neurochem 116(5):926-935.
45. Rajesh M, Kolmakova A, Chatterjee S (2005) Novel role of lactosylceramide in vascular endothelial growth factor-mediated angiogenesis in human endothelial cells. Circ Res 97(8):796-804.
46. Bejaoui K, et al. (2002) Hereditary sensory neuropathy type 1 mutations confer dominant negative effects on serine palmitoyltransferase, critical for sphingolipid synthesis. J Clin Invest 110(9):1301-1308.
47. Sugita M, Dulaney JT, Moser HW (1972) Ceramidase deficiency in Farber's disease (lipogranulomatosis). Science 178(4065):1100-1102.
48. Ferraiuolo L, et al. (2011) Dysregulation of astrocyte-motoneuron cross-talk in mutant superoxide dismutase 1-related amyotrophic lateral sclerosis. Brain 134(Pt 9):2627-2641.
49. Kohyama-Koganeya A, et al. (2004) Drosophila glucosylceramide synthase: A negative regulator of cell death mediated by proapoptotic factors. J Biol Chem 279(34):35995-36002.
50. Dodge JC, et al. (2013) Metabolic signatures of amyotrophic lateral sclerosis reveal insights into disease pathogenesis. Proc Natl Acad Sci USA 110(26):10812-10817.